Latest Regulatory Approval News

New Hope Corporation Limited (ASX:NHC) has lifted its reported coal resources to 2.96 billion tonnes, driven by major model updates at Bengalla and New Acland. The larger inventory comes with important qualifications: much of Bengalla’s addition is inferred, while a substantial portion of New Acland’s reserves still depends on future approvals.

Cygnus Metals shareholders delivered overwhelming proxy support for Central Asia Metals’ proposed takeover, but the transaction still faces a Kazakhstan regulatory decision and possible court-date delay. Final poll results were not included in the chairman’s address and are expected separately.

MAAS Group has received FIRB approval for the sale of its construction materials division to Heidelberg Materials Australia, leaving shareholder approval and an Asphalt Operators acquisition as the key remaining conditions. Settlement remains targeted for October 2026, with transaction terms unchanged.

Mandrake Resources has secured the final regulatory approval for a planned 3,200-metre gold-copper drilling programme at its Berinka project in the Northern Territory. Mobilisation is scheduled for October, putting the company’s next exploration milestone within reach.

Ionic Rare Earths is pushing toward commercial magnet recycling in Belfast and the United States, but its FY2026 report flags a material uncertainty over its ability to continue as a going concern. The company reported a larger A$14.9 million loss and A$13.9 million in operating cash outflows, despite government support and new strategic partnerships.

Latrobe Magnesium has received a non-binding US$15 million Letter of Support from a confidential US financial institution for the feasibility study on its proposed 50 ktpa South Carolina magnesium plant. The funding remains conditional on matching finance, due diligence, approvals and definitive agreements.

Atlantic Lithium has secured Australian foreign investment approval for Zhejiang Huayou Cobalt’s proposed acquisition, removing one condition to the scheme. Shareholder, court and other regulatory approvals are still required before the transaction can complete.

Patrys has formed an international Clinical Advisory Committee to help shape the next stages of RLS-2202, its injectable quetiapine candidate for delirium in acute-care settings. The appointments add recognised expertise in delirium research, intensive care and trial design, but do not yet provide clinical efficacy or regulatory evidence.

Zinc of Ireland has transformed from a small Irish zinc explorer into a metals technology developer, acquiring Meclex, raising A$5.5 million and advancing ARGO and VOLTA. The opportunity is substantial, but both technologies remain uncommercialised and the VOLTA partnership requires formal renewal.

Horizon Oil has used its Pareto Securities presentation to put record FY26 production, enlarged reserves and a multi-country drilling pipeline at the centre of its growth case. The stronger platform comes with a test: convert a long list of projects into sustained cash flow while preserving shareholder returns.

Emyria has presented its regulated Australian psychedelic-treatment experience to the US FDA, putting clinical delivery systems rather than drug development at the centre of its US ambitions. The appearance raises the company’s profile, but does not yet disclose regulatory approval, a commercial agreement or a financial commitment.

Reliance Worldwide Corporation has signed a binding scheme implementation deed for Brookfield to acquire all shares for US$3.38 each, equivalent to about A$4.75 at the stated exchange rate. The recommended deal now enters a limited window for rival proposals before shareholder, court and regulatory approvals are sought.